Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
Black Diamond Therapeutics, Inc. | Officer Title: Chief Operating Officer and General Counsel | Stock Option (Right to Buy) | 200K | Feb 14, 2024 | Direct |
Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
---|---|---|---|---|---|---|---|
BDTX | Black Diamond Therapeutics, Inc. | Feb 14, 2024 | 1 | $0 | 4 | Feb 15, 2024 | Officer Title: Chief Operating Officer and General Counsel |
BDTX | Black Diamond Therapeutics, Inc. | Feb 13, 2023 | 1 | $0 | 4 | Feb 15, 2023 | Officer Title: Chief Operating Officer and General Counsel |
BDTX | Black Diamond Therapeutics, Inc. | Feb 15, 2022 | 1 | $0 | 4 | Feb 17, 2022 | Officer Title: Chief Operating Officer and General Counsel |
BDTX | Black Diamond Therapeutics, Inc. | May 12, 2021 | 5 | -$98.8K | 4 | May 13, 2021 | Chief Operating Officer and General Counsel |